BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Aaron Berg is Amarin’s new COO

23 April 2018 | News

Mr. Berg previously served the company as Senior Vice President, Marketing and Sales. Mr. Berg joined Amarin in November of 2012 and has played a leading role in U.S. prescription and related revenue growth of the company’s lead product, Vascepa (icosapent ethyl) capsules.

Singapore – Amarin Corporation, a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular (CV) health, announced that Aaron Berg has been promoted to the position of Senior Vice President, Chief Commercial Officer. Mr. Berg previously served the company as Senior Vice President, Marketing and Sales. Mr. Berg joined Amarin in November of 2012 and has played a leading role in U.S. prescription and related revenue growth of the company’s lead product, Vascepa (icosapent ethyl) capsules.

In this expanded role, Mr. Berg will be responsible for ensuring continued commercial growth for Vascepa based on its current indication while preparing for and ensuring successful expanded promotion of Vascepa assuming positive results of the company’s landmark REDUCE-IT cardiovascular outcomes trial. The results of this important study are anticipated before the end of Q3 2018. The company thanks Mark Salyer, whose position is being filled by Mr. Berg, for his ideas and contributions and wishes him much success in his future endeavors.

"Aaron has made invaluable contributions to Amarin over multiple years,” said John F. Thero, President and Chief Executive Officer of Amarin. “He has wide-ranging experience and comprehensive knowledge of our industry combined with an entrepreneurial spirit and a collaborative approach which makes him broadly respected and well-positioned to help lead Amarin in fulfilling our commercial opportunities. We are excited to work with Aaron in this important leadership position.”